Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011570 (depression)
 172,036 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A combined behavioral-psychodynamic treatment for severe, chronic stomach pain has been presented. In the case discussed, neither psychotherapy nor behavior therapy alone was successful in dealing with the patient's somatized depression. Aversive conditioning was credited with eliminating verbal report of pain and subjective sensation of chronic gastric pain. Simultaneous with the reduction in pain, however, the patient became increasingly depressed. Analytically oriented psychotherapy was instrumental in resolving the depression.
 ...
PMID:Aversive behavior therapy for chronic stomach pain: a case study. 92 82

The aim of this study was to verify long-term therapeutic efficacy and tolerance of dihydroergocristine (DHEC, CAS 17479-19-5) in a double blind placebo controlled study, in elderly patients with psychosyndrome characterized by memory and behaviour impairment. Two hundred patients, aged more than 65 years, were randomly divided into two groups of one hundred each. The first group received one 6-mg DHEC tablet daily for four months and the other group received placebo. The evaluation parameter for efficacy was the neuropsychological test SCAG (Scale of Clinical Assessment for Geriatrics), administered before and after 30, 60 and 120 days. The results showed a significant difference between DHEC and placebo with regard to total and partial scores of SCAG as well as to single items (mental alertness, recent memory, disorientation, anxiety, mood depression, emotional lability, motivation, uncooperativeness, fatigue, headache, tinnitus). After as few as thirty days of DHEC treatment the severity of mental and psychological symptoms was markedly decreased (p vs placebo < 0.01), as documented by significant positive changes of SCAG items. The four-month double blind period was followed by a two-month single blind period, during which patients of both groups received placebo. At the end of these two months, SCAG total score was unfavourably increased in patients previously administered DHEC, although scores were still significantly lower both versus baseline and versus previous placebo patients. Safety was good (placebo: one case of diarrhea; DHEC: one case of gastralgia and dizziness). Nine patients dropped out for reasons unrelated to treatment.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Controlled study of the effect of dihydroergocristine on organic brain psychosyndrome]. 149 63

The antianginal efficacy of metoprolol OROS has been investigated in comparison with that of atenolol in a multicenter double-blind cross-over trial carried out in patients with stable effort angina. OROS (ORally OSmotic) is a new semi-permeable delivery system with very slow osmotic release of the active drug, which is maintained at virtually constant plasma levels throughout the 24 hours. At the end of a 2-week run-in period, 53 patients with chronic coronary artery disease and documented ischemia during bicycleergometric exercise test were given, on double-blind condition, metoprolol OROS 21/285 and atenolol 100 mg in random order for 4 weeks each. On the last day of each cross-over period, patients underwent a bicycleergometric exercise test 24 hours after the last drug intake. The mean number of anginal attacks (2.54 during the 2-week run-in period) decreased under both metoprolol OROS (1.29 and 1.13 after 2 and 4 weeks of treatment, respectively) and atenolol (1.29 and 0.73 after 2 and 4 weeks of treatment, respectively), with no difference between the two beta-blockers. The same behaviour was observed as regards the nitroglycerin tablets consumption. The exercise test variables (i.e. duration of exercise, maximum workload and peak exercise values of systolic and diastolic blood pressure, heart rate and ST-segment depression) did not differ between the two treatments and did not show a time-effect. The percentage of patients reporting adverse effects was low with both treatments. Two patients were withdrawn from the study during atenolol (gastralgia and heartburn, respectively), and one during metoprolol OROS (gastralgia).(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:A comparison of metoprolol OROS with antenolol in the treatment of effort angina pectoris: a randomized double-blind study. 190 34

Of the 109 specialist female physical education students who answered a detailed questionnaire on menstruation and the contraceptive pill in relation to exercise, 91 (83.5%) reported that they suffered menstrual problems. These included stomach ache, depression, abdominal cramps, and backache. Over 2/3 of the students considered that these problems adversely influenced their physical performance. However, whether they had a mainly physiological or psychological effect is not clear. Many of the students with menstrual problems thought that exercise had a beneficial effect and helped alleviate their discomfort. A small number of students reported problems such as amenorrhea and reduced menses possibly due to excessive training. Just under 1/2 of the students in the investigation took OCs, and though as many students taking the pill complained of menstrual problems as those not taking it, they reported less problems and to a lesser degree. Most students claimed that taking OCs had no effect on their performance.
 ...
PMID:Effects of menstruation and contraceptive pill on the performance of physical education students. 685 Feb 5

612 patients with different psychosomatic disorders of gastrointestinal tract (GIT) were examined. They included either 200 patients with organic stomach disease or with duodenal ulcer as well as 412 individuals with various functional disorders of GIT such as psychogenic vomiting, dysphagia, gastralgia and colon irritability syndrome. In 70% of all cases patientc relatives (1-3 degree of relationship) had also some psychosomatic diseases. All the patients suffered in childhood from so-called GIT-variant of children's neuropathia. Being adults they all met intensive or moderate stress and developed psychogenic depression. Two ways of psychosomatic disorders cristallization on the background of depression were observed, exactly reactivation of children's neuropathia symptomes or rapid affect somatization which were followed by psychosomatic cycles formation and by stress tolerance decrease. Several types of psychosomatic development were described: hypochondrial (78.8%), asthenic (12.4%), obsessive (2.3%), hysterical (4.4%) and paranoial (2.1%).
 ...
PMID:[Variants of psychosomatic personality development in diseases of the gastrointestinal tract]. 878 77

This article presents data from two avenues of marijuana research. First, the author shows that daily marijuana smoking in healthy individuals produces dependence, as demonstrated by withdrawal symptoms such as increased irritability and depression and decreased food intake. In addition, two antidepressant medications were evaluated to assess their potential effectiveness in the treatment of marijuana withdrawal symptoms: (1) sustained-release bupropion (0, 300 mg/day) and (2) nefazodone (0, 450 mg/day). Research participants were regular marijuana smokers who lived in a residential laboratory in groups of two to four. While inpatients, participants smoked active marijuana (2.8%-3.1% THC) repeatedly for 4 days, followed by 8 to 12 days of placebo marijuana (0.0% THC). Results show that during marijuana abstinence, (1) bupropion increased ratings of irritability, depression, and stomach pain and decreased food intake and sleep quality compared to placebo maintenance, and (2) nefazodone decreased anxiety during marijuana withdrawal but did not alter ratings of irritability and misery. Thus, neither medication showed promise as potential treatments for symptoms of marijuana withdrawal. The second avenue of research focused on the effect of cannabinoids in individuals with muscle mass loss, an indicator of wasting in HIV illness. Given that there are little scientific data contributing to the debates concerning medical marijuana, this study directly compared the effects of oral delta9-THC (0, 10, 20, 30 mg PO) to smoked marijuana (0.0%, 1.8%, 2.8%, 3.9% THC) in HIV + marijuana smokers with muscle mass loss (< 90% body cell mass/height). Multiple dimensions of human behavior were measured, including food intake, mood, and cognitive performance. Drugs were administered using a within-subject, double-blind, staggered, double-dummy design. Participants were free to self-select from a variety of foods throughout most of the session. Preliminary data (n = 9) suggest that oral THC was more effective at increasing food intake, but the volunteers "liked" the effects of smoked marijuana more than the effects of oral THC.
 ...
PMID:Effects of smoked marijuana in healthy and HIV + marijuana smokers. 1241 34

Psychiatric and psychological examinations of 100 patients (80 females and 20 males) with functional gastralgia (ICD-10 diagnosis F45.31) have been conducted. In all the cases, the disease developed in chronic stress in persons with higher anxiety inclined to mild anxious and depressive reactions. Four stages of the disease development were described: reactive (neurotic) depression, psychosomatic reactions, psychosomatic cycles (mono- and polysystemic) and psychopathization. Development of psychosomatic personality was expressed as hypochondriac type.
 ...
PMID:[Functional gastralgia]. 1244 62

Major depressive disorder is a medical condition that includes abnormalities of affect and mood, cognition, and physical functioning. In particular, as many as 76% of patients suffering from depression are found to report somatic symptoms, including various types of pain such as headaches, stomach pain, back pain, and vague, poorly localized pain. Although the pathophysiology of depression is still unknown, there is significant evidence for abnormalities of the norepinephrine (NE) and serotonin (5-HT) neurotransmitter systems in depressive disorders. Interestingly, both 5-HT and NE also appear to exert analgesic effects via descending pain pathways and therefore play a modulating role in pain. There are many effective antidepressant treatments available. However, residual symptoms are relatively common, among both partial responders and responders without remission. A recent study from our group has shown that responders who have not achieved remission have significantly more somatic symptoms than remitters following 8 weeks of treatment with fluoxetine. These data may suggest that antidepressants that are particularly effective in the treatment of pain and painful physical symptoms may yield higher remission rates in major depressive disorder.
 ...
PMID:The role of the serotonergic and noradrenergic neurotransmitter systems in the treatment of psychological and physical symptoms of depression. 1455 53

Over 75% of depressed patients in primary care complain of painful physical symptoms such as headache, stomach pain, neck and back pain as well as non-specific generalized pain. The presence of such symptoms predicts a greater severity and a less favourable outcome of depression with a poorer health-related quality of life. World Health Organization data obtained in primary care centres worldwide show that 22% of all primary care patients suffer from persistent debilitating pain and that these patients are four times more likely to have co-morbid anxiety or depressive disorder than pain-free primary care patients. Not unexpectedly, the risk of depression is greater when the pain is more diffuse, as indicated by the number of painful sites, and has a greater effect on the quality of life. Certain depressive symptoms, such as low energy and sleep disturbances, are commonly found in patients with co-morbid pain, whereas the opposite is true for symptoms such as guilt and loneliness. Increasingly, major depression is seen as being composed of psychological, somatic and painful physical symptoms. In order to achieve full sustained remission it is necessary to treat symptoms in all three of these areas. The area of painful physical symptoms is unfortunately still poorly understood and clearly merits greater attention.
 ...
PMID:The epidemiology of pain in depression. 1537 70

The main aim of the study was a search for factors influencing efficacy of movalis used in combined form, injection and tablets, for the treatment of patients with acute back pain syndrome (BPS) and evaluation of the drug safety. Thirty patients, 18 female, 12 male, mean age 43.1 years, with primary BPS have been studied. In 83% of patients, BPS was caused by muscle tonic syndrome and in 17% the latter was combined with radiculopathy. Meloxicam therapy was conducted using intramuscular injections of 15 mg daily during 5 days with following oral drug intake (1 tablet daily). Treatment duration was 2 weeks. This treatment regime proved to be highly effective. The subjective meloxicam efficacy was the following: moderate--7%; good--30%; very good--33%; excellent--30%. Side effects, such as transient stomach pain, was observed only in 6.6% of patients. The main factors reducing meloxicam efficacy were affective disorders, namely, a level of depression and anxiety, and radiculopathy.
 ...
PMID:[Efficacy of movalis in the treatment of acute low back pains]. 1611 44


1 2 3 Next >>